It’s the era of at-home health diagnostics and Senzo is finding its flow

It’s the era of at-home health diagnostics and Senzo is finding its flow

Biotech company Senzo just raised a $2 million round at a $20 million pre-money valuation to further extend options for lateral flow diagnostics. “Lateral flow,” in this case, is the same type of testing you’ve seen from at-home pregnancy or COVID-19 tests. The company is creating a product it calls Amplified Lateral Flow (ALF). For […]

This content has been restricted to logged in users only. Please login to view this content.